Formoterol dry-powder inhalation - Novartis/SkyePharma

Drug Profile

Formoterol dry-powder inhalation - Novartis/SkyePharma

Alternative Names: Foradil Certihaler; Foradil MDDPI; Foradil MDPI; Foradil SkyeHaler; Formoterol Certihaler; Formoterol fumarate dry-powder inhalation - Novartis/SkyePharma

Latest Information Update: 22 Jul 2009

Price : $50

At a glance

  • Originator SkyePharma PLC
  • Class Antiasthmatics; Bronchodilators; Ethanolamines; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Market Withdrawal Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 24 Jul 2013 Biomarkers information updated
  • 17 Jul 2009 SkyePharma terminates its contracts with Novartis & a subcontractor for Formoterol Certihaler
  • 19 Dec 2008 Discontinued - Registered for Asthma in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top